Vincent Hansen

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 854 citations

End-of-study Results, Breast Oncology, Medicine +8

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Sung‐Bae Kim, Rebecca Dent, Seock‐Ah Im et al. · The Lancet Oncology · 2017 · 463 citations · Full text

First-line Therapy, Breast Oncology, Medicine +7

Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer

Beth Y. Karlan, Amit M. Oza, Gary Richardson et al. · Journal of Clinical Oncology · 2011 · 225 citations · Full text

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial

CH Barcenas, Sara A. Hurvitz, Jack A. Di Palma et al. · Annals of Oncology · 2020 · 102 citations · Full text